PT3060211T - Tratamento de cancro e distúrbios proliferativos benignos. - Google Patents

Tratamento de cancro e distúrbios proliferativos benignos.

Info

Publication number
PT3060211T
PT3060211T PT147958540T PT14795854T PT3060211T PT 3060211 T PT3060211 T PT 3060211T PT 147958540 T PT147958540 T PT 147958540T PT 14795854 T PT14795854 T PT 14795854T PT 3060211 T PT3060211 T PT 3060211T
Authority
PT
Portugal
Prior art keywords
cancer
treatment
proliferative disorders
benign proliferative
benign
Prior art date
Application number
PT147958540T
Other languages
English (en)
Inventor
Hampson Ian
Hampson Lynne
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201318742A external-priority patent/GB201318742D0/en
Priority claimed from GB201409362A external-priority patent/GB201409362D0/en
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of PT3060211T publication Critical patent/PT3060211T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT147958540T 2013-10-23 2014-10-23 Tratamento de cancro e distúrbios proliferativos benignos. PT3060211T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201318742A GB201318742D0 (en) 2013-10-23 2013-10-23 Treatment of cancer
GB201409362A GB201409362D0 (en) 2014-05-27 2014-05-27 Treatment of cancer

Publications (1)

Publication Number Publication Date
PT3060211T true PT3060211T (pt) 2019-10-25

Family

ID=51868985

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147958540T PT3060211T (pt) 2013-10-23 2014-10-23 Tratamento de cancro e distúrbios proliferativos benignos.

Country Status (9)

Country Link
US (2) US9782409B2 (pt)
EP (2) EP3060211B1 (pt)
AU (1) AU2014338707B2 (pt)
CA (1) CA2928166C (pt)
ES (1) ES2749131T3 (pt)
HU (1) HUE046728T2 (pt)
PL (1) PL3060211T3 (pt)
PT (1) PT3060211T (pt)
WO (1) WO2015059485A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3060211B1 (en) 2013-10-23 2019-09-18 The University Of Manchester Treatment of cancer and benign proliferative disorders
US10588564B2 (en) 2014-09-30 2020-03-17 Moein Health, LLC Method and kit for diagnosing and treating neoplastic tissue
US20160279083A1 (en) * 2015-02-24 2016-09-29 Moein Health, Inc. Topical treatment for cervical intraepithelial neoplasia
KR102327809B1 (ko) * 2015-02-18 2021-11-17 인터플렉스 인더스트리즈 인코포레이티드 다층 버스 보드
EP3681494A4 (en) * 2017-09-15 2021-08-04 Ampersand Biopharmaceuticals, Inc. INHIBITION OF SPONTANEOUS METASTASIS BY PROTEIN INHIBITORS OF CYSTEIN PROTEASES
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808567D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201808571D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201808563D0 (en) * 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053694A1 (en) 2003-11-28 2005-06-16 The University Of Manchester Treatment of hpv infections and cancer
US9005889B2 (en) * 2007-01-16 2015-04-14 The Johns Hopkins University Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor
GB201115635D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
EP3060211B1 (en) 2013-10-23 2019-09-18 The University Of Manchester Treatment of cancer and benign proliferative disorders

Also Published As

Publication number Publication date
EP3060211B1 (en) 2019-09-18
EP3603637A1 (en) 2020-02-05
US9782409B2 (en) 2017-10-10
US20160271132A1 (en) 2016-09-22
US10251884B2 (en) 2019-04-09
HUE046728T2 (hu) 2020-03-30
AU2014338707B2 (en) 2020-06-04
US20180161328A1 (en) 2018-06-14
CA2928166A1 (en) 2015-04-30
CA2928166C (en) 2022-07-19
ES2749131T3 (es) 2020-03-19
EP3060211A1 (en) 2016-08-31
PL3060211T3 (pl) 2020-07-27
WO2015059485A1 (en) 2015-04-30
AU2014338707A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
HK1216991A1 (zh) 癌疫苗及使用其的治療方法
HUE046728T2 (hu) Rák és jóindulatú proliferációs rendellenességek kezelése
ZA201602380B (en) Cancer treatment with combination of plinabulin and taxane
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
HK1221145A1 (zh) 用二氫吡嗪並-吡嗪治療癌症
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
HK1221150A1 (zh) 用二氫吡嗪並-吡嗪類對癌症的治療
GB201607581D0 (en) Treatment of cancer
HK1232118A1 (zh) 癌症的治療
TWI561255B (en) Use of umirolimus and its derivatives for treating cancer
GB201317373D0 (en) Treatment and prevention of cancer
GB201322346D0 (en) Combination treatment of cancer
SG10201802995SA (en) Cancer treatment with combination of plinabulin and taxane
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
GB201322958D0 (en) Uses of oligouronates in cancer treatment
GB201301685D0 (en) Diagnosis and treatment of cancer